Patients with renal cancer do not need adjuvant therapy after surgery

Surgery is the first choice of treatment for kidney cancer patients and is currently the only way to cure the tumor. However, some patients need adjuvant treatment after surgery, and doctors usually give advice. However, many patients actively request adjuvant treatment because they are worried that the tumor will recur or metastasize after surgery. Some informal hospitals will also recommend patients to undergo informal adjuvant treatment, which not only wastes the patient's money, but also has an adverse effect on the patient's disease treatment.

In fact, for general early-stage renal cancer patients, if they have undergone radical surgery or kidney-preserving surgery, they do not need special adjuvant treatment. They only need to follow the doctor's instructions for regular checkups. At this time, additional adjuvant treatments such as radiotherapy and chemotherapy will not only not reduce the incidence of tumor recurrence and metastasis, but will also bring many unnecessary adverse reactions to patients. There is no need for adjuvant chemotherapy and radiotherapy for early-stage renal cancer, nor is there any need for interferon or interleukin immunotherapy, let alone auxiliary targeted therapy. These additional adjuvant treatments not only have no special effect on the tumor, but also produce side effects of the drugs and even affect kidney function. High-dose interferon and interleukin immunotherapy and drug targeted therapy are aimed at middle and late-stage renal tumors, and they should be used selectively for middle and late-stage tumors to avoid adverse effects on patients.